C24-Ceramide

C24-Ceramide is an orally active competitive binding agonist of PIP4K2C (mTOR complex regulator), thereby activating the mTOR signaling pathway. At the same time, C24-Ceramide changes the membrane morphology by inducing the formation of a partially interlocked gel phase in the phospholipid bilayer. C24-Ceramide can promote the proliferation and migration of keratinocytes to accelerate skin wound healing and drive the proliferation and metastasis of gallbladder cancer cells. The level of C24-Ceramide in serum can be used as a diagnostic marker for gallbladder cancer[1][2][3].

Product Specifications

CAS Number

[34435-05-7]

UNSPSC

12352211

Hazard Statement

H302, H315, H319, H335

Target

MTOR

Type

Reference compound

Related Pathways

PI3K/Akt/mTOR

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/c24-ceramide.html

Purity

99.92

Solubility

DMSO : < 1 mg/mL (ultrasonic; warming) |Ethanol : 25 mg/mL (ultrasonic) |THF : 25 mg/mL (ultrasonic)

Smiles

CCCCCCCCCCCCCCCCCCCCCCCC(N[C@@H](CO)[C@H](O)/C=C/CCCCCCCCCCCCC)=O

Molecular Formula

C42H83NO3

Molecular Weight

650.11

Precautions

H302, H315, H319, H335

References & Citations

[1]Ventura AE, et al. Lipid domain formation and membrane shaping by C24-ceramide. Biochim Biophys Acta Biomembr. 2020 Oct 1;1862 (10) :183400.|[2]Lee JH, et al. C24 Ceramide Lipid Nanoparticles for Skin Wound Healing. Pharmaceutics. 2025 Feb 12;17 (2) :242.|[3]Zhang Y, et al. C24-Ceramide Drives Gallbladder Cancer Progression Through Directly Targeting Phosphatidylinositol 5-Phosphate 4-Kinase Type-2 Gamma to Facilitate Mammalian Target of Rapamycin Signaling Activation. Hepatology. 2021 Feb;73 (2) :692-712.